IAM
HRMY icon

Iridian Asset Management’s Harmony Biosciences HRMY Stock Holding History

Iridian Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-42,597
Closed -$1.2M – 104
2021
Q2 		$1.2M Buy
+42,597
New +$1.28M 0.02% 75

Other funds holding HRMY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Iridian Asset Management's HRMY Position: Q3 2021 in Review

Iridian Asset Management sold out of Harmony Biosciences (HRMY) in Q3 2021, closing a stake of 42,597 shares — an estimated $1.2M sold.

Iridian Asset Management first reported a position in HRMY in Q2 2021 and held it in 1 quarter. The position peaked at $1.2M in Q2 2021. 102 funds tracked by Wall St. Rank hold HRMY as of Q3 2021.

  • Iridian Asset Management reported no remaining Harmony Biosciences position as of Q3 2021 after selling out during the quarter.
  • Iridian Asset Management sold 42,597 Harmony Biosciences shares in Q3 2021, an estimated $1.2M.
  • Iridian Asset Management first reported a position in Harmony Biosciences in Q2 2021 and held it in 1 quarter.
  • Iridian Asset Management's Harmony Biosciences position peaked at $1.2M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2021.

Based on Iridian Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.